NEW YORK - SELLAS Life Sciences Group, Inc. (NASDAQ:SLS), a biopharmaceutical company with a market capitalization of $81 million engaged in developing cancer therapies, has announced a registered ...
Some results have been hidden because they may be inaccessible to you